Home » 2023

Yearly Archives: 2023

High Dose Vitamin D Supplements and Breastfeeding

The question as to the compatibility of high dose vitamin d supplements in the breastfeeding mother is a frequently asked question. We appear to monitor levels more frequently than we did in the past but research is difficult to source. I hope this information helps.

pdf of this information.

High dose vitamin d supplement for breastfeeding mothers factsheet

There has been an unexpected increase over the past 15 years in the number of babies found to be suffering from rickets or symptoms of decreased bone mass which demonstrate poor levels of vitamin D (NICE PH11). Vitamin D deficiency is unusual in babies born at term to mothers with adequate vitamin D status. Some women enter pregnancy with low vitamin D levels. This may be due to:

•             lack of exposure to sunlight due to wearing concealing clothing for cultural reasons;

•             inadequate consumption of foods containing vitamin D e.g. oily fish;

•             Inadequate consumption of dairy (prevalent particularly in adolescent girls)

•             BMI greater than 30;

•             Women who spend a lot of time indoors or use sun creams limiting the absorption of ultraviolet (UV) light;

•             living in the northern hemisphere where levels of UV light are only sufficient to stimulate vitamin D production in the summer months; and

•             having dark skin, which prevents absorption of available UV light in the UK climate.

Babies born to mothers with low vitamin D levels may be born deficient. In turn this will be exacerbated by being breastfed as the vitamin D levels in breastmilk will be sub-optimal.

In 2016 SACN amended recommendations so that breastfed babies from birth to one year of age should be given a daily supplement containing 8.5 to 10mcg of vitamin D as a precaution and breastfeeding mothers should also take a daily Vitamin D supplement of 10 µg (400IU) per day

This in no way suggests that the breastmilk of a mother with low levels of vitamin D, does not have all the other health advantages but is a reflection of current awareness of the risk of sun damage in sunlight balanced with the UK climate and poor levels of sunshine for the majority of the year. Breastfeeding alone cannot redress the deficiency resulting from low levels in pregnancy. Vitamin D is a fat-soluble vitamin that is found in food and can also be made in the body after exposure to UV rays from the sun. Fortified foods are common sources of vitamin D but without sunshine exposure it is difficult to achieve maximal intake. Supplements can be taken as part of multi-vitamin products or with calcium.

Sources of vitamin D

•             More than 90% of mankind’s vitamin D supply is derived from UVB sunlight exposure

•             Oily fish including trout, salmon, mackerel, herring, sardines, anchovies, pilchards and fresh tuna

•             Cod liver oil and other fish oils

•             Egg yolk – 0.5 µg (20 IU) per yolk

•             Mushrooms

•             Supplemented breakfast cereals, mainly supermarket ‘own brands’ in the UK. Typically contain between 2 and 8 µg (80-320 IU) per 100 g

•             Margarine

In a fair-skinned individual, exposure of the face and forearms to 20–30 minutes of sunlight at midday is estimated to generate the equivalent of 2000 IU vitamin D. Between April and October all of Scandinavia, much of western Europe, including 90% of the UK (roughly north of Birmingham) and 50% of USA is above the latitude where exposure to sufficient UVB is possible (Pearce 2010).

High dose vitamin d supplements

Many breastfeeding mothers appear to be being diagnosed as vitamin D deficient and prescribed high doses daily or weekly. Hollis et al 2015 reported that “Maternal vitamin D supplementation with 6400 IU/day safely supplies breast milk with adequate vitamin D to satisfy her nursing infant’s requirement and offers an alternate strategy to direct infant supplementation. With the use of higher dose supplements the mother should observe the baby for signs of hyper calcaemia (nausea, vomiting, weight loss, thirst, muscle weakness and confusion) and if observed blood test the baby.

Hollis and Wagner (2004) studied 18 women exclusively breastfeeding one month after delivery, and gave half 1600 IU vitamin D2 and 400 IU vitamin D3 and the others 3600 IU vitamin D2 and 400 IU vitamin D for 3 months. Blood, urine, and milk samples were obtained from the mothers at months 1, 2, 3, and 4 of lactation. Infant blood was collected at months 1 and 4 (beginning and end of the study). Maternal blood was monitored for total calcium, vitamin D2, vitamin D3, 25(OH)D2, and 25(OH)D3 concentrations. Infant serum was monitored for vitamin D2, vitamin D3, 25(OH)D2, 25(OH)D3, calcium, and phosphorus concentrations. The conclusion of the study was that the 400iu per day has been recommended arbitrarily and needs further research. In the study maternal vitamin D intakes of ≥4000 IU/d appear to be safe and to provide sufficient vitamin D to ensure adequate nutritional vitamin D status for both mothers and nursing infants.

  • Hollis BW, Wagner CL, Vitamin D requirements during lactation: high-dose maternal supplementation as therapy to prevent hypovitaminosis D for both the mother and the nursing infant, Am J Clin Nutr, 2004;80(6 Suppl.):1752S–8S. (https://academic.oup.com/ajcn/article/80/6/1752S/4690524)

Hollis et al (2015) randomised 3 groups of exclusively breastfeeding women to 400 IU vitamin D3 per day 2400 IU or 6400 IU vitamin D3 per day, The infants of the mothers in group one were given a vitamin d supplement but those in the higher dose groups received placebo drops. 148 mothers completed the full study still exclusively breastfeeding. The conclusion of the study was that maternal vitamin D supplementation with 6400 IU/day safely supplies breast milk with adequate vitamin D to satisfy her nursing infant’s requirement and offers an alternate strategy to direct infant supplementation. This was not achieved with lower doses.

Some mothers are prescribed 20,000 or 40,000 units once weekly which approximate to a similar dosage. There is limited research to support this level being compatible with breastfeeding so the baby should be monitored for hypercalcaemia as described above – nausea, vomiting, weight loss, thirst, muscle weakness and confusion

See also: https://www.ncbi.nlm.nih.gov/books/NBK500914/

https://www.sps.nhs.uk/articles/using-vitamin-d-during-breastfeeding (December 2023)

For full references see Breastfeeding and Medication 2018

Opioids and breastfeeding

When paracetamol plus a non steroidal drug (ibuprofen, naproxen, diclofenac or celecoxib) are insufficient to control pain opioid drugs may need to be used. They cause constipation so should be co prescribed with a stool softener). They are also addictive so should be used for the shortest possible time, in the lowest possible dose.

Codeine is not recomemnded for breastfeeding https://breastfeeding-and-medication.co.uk/thoughts/breastfeeding-and-codeine but one accidental dose or short term use, maybe overnight when no other pain relief is available does not mean that breastfeeding needs to be interrupted.

No breastfeeding mother should ever be asked to choose between adequate pain relief and breastfeeding

Opioids and breastfeeding factsheet

Mirtazapine and breastfeeding

Another medication used during breastfeeding for anxiety and depression is mirtazapine. It may be used where other SSRIs have not been effective or tolerated. Mirtazapine may be also be seen as an option where insomnia is a symptom of  anxiety or depression.

The baby should be observed for signs of drowsiness and ineffective feeding.

Care should be taken with co sleeping because it is likely to cause drowsiness in the lactating mother. Falling asleep in chairs or on sofas should be regarded as an even greater risk https://www.basisonline.org.uk/

LactMed summarises that “Limited information indicates that maternal doses of up to 120 mg daily produce low levels in milk and would not be expected to cause any adverse effects in breastfed infants, especially if the infant is older than 2 months.” In practice the normal dose is 15mg taken at night.

Professionals may find the RCGP Perinatal mental health toolkit a useful resource https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/perinatal-mental-health-toolkit.aspx

See also https://www.sps.nhs.uk/articles/using-duloxetine-mirtazapine-trazodone-or-venlafaxine-during-breastfeeding

The information in this factsheet is taken from my book Breastfeeding and Medication. Please message me with queries or the references used. wendy@breastfeeding-and-medication.co.uk

Mirtazapine and Breastfeeding Factsheet

Rivaroxaban and other anticoagulants and breastfeeding

For many years the standard anti coagulants to treat and prevent deep vein thrombosis (DVT) have been heparin and low molecular weight heparionoids e.g Enoxaparin (Clexane®)  or alternately but generally less frequently Tinzaparin (Innohep®), Dalteparin (Fragmin®, Fondaparinux (Arixtra®). Alternatively warfarin may be given as a tablet but generally takes too long to stabilise the clotting mechanism. All of these drugs are compatible with breastfeeding. The sub cutaneous injections are too large molecules which cannot be absorbed from breastmilk (are not orally bio-available). Because of the very low milk levels with warfarin doses less than 12 mg daily, amounts ingested by the infant are small. No adverse reactions in breastfed infants have been reported from maternal warfarin use during lactation, even with a dose of 25 mg daily for 7 days. There is a consensus that maternal warfarin therapy during breastfeeding poses little risk to the breastfed infant. No special precautions are necessary. (Lactmed https://www.ncbi.nlm.nih.gov/books/NBK501137/).

See also Using heparins during breastfeeding Jan 2024 https://www.sps.nhs.uk/articles/using-heparins-during-breastfeeding/

Although these drugs are not absorbed from milk, caution is recommended where there is donation to a milk bank of surplus breastmilk. Should any small amount reach a pre-term baby it may result in a bleed with catastrophic results. There are no studies to confirm this but the recommendation is made to protect these most vulnerable babies.

Deep vein thrombosis

Whilst DVTs are uncommon they are 5 times more common in pregnancy and in the first 6 weeks after delivery than in women who are not pregnant.

The risk of developing DVT during pregnancy is even greater if :

  • there is a history or family history of DVT
  • age over 35
  • obese BMI >30
  • a severe infection or recent serious injury, which restrict exercise
  • thrombophilia
  • multiple birth
  • after fertility treatment
  • after a caesarean section
  • currently smoke
  • have severe varicose veins
  • dehydration


If the clot breaks off into the bloodstream, it can block a blood vessel in the lungs. This is called a pulmonary embolism (PE) and needs emergency treatment. It may be investigated by a VQ or CT scan (preferably the latter as it involves no interruption of breastfeeding . See https://breastfeeding-and-medication.co.uk/fact-sheet/breastfeeding-after-vq-scans

The newer treatments to prevent clots are called Direct Oral Anticoagulant Medications (DOAC) which have advantages in that they are oral medications and need less frequent blood tests to confirm the INR.

UKDILAS have produced an excellent summary https://www.sps.nhs.uk/articles/using-oral-anticoagulants-in-breastfeeding-women/

Rivaroxaban  (Xarelto®): compatible with breastfeeding

  • Doses from breastmilk are over 100 times lower than doses given directly to pediatric patients. (Hale).
  • Several case reports consistently indicate that maternal doses of rivaroxaban of 15 to 30 mg daily produce low levels in milk that are considerably below doses required for anticoagulation in infants (Lactmed https://www.ncbi.nlm.nih.gov/books/NBK500742/.
  • Its pharmacokinetic data (large volume of distribution and high percentage of protein binding) explain the very small passage to milk observed in four different cases (Zhao 2020, Muysson 2019, Saito 2019, Wiesen 2016). https://www.e-lactancia.org/breastfeeding/rivaroxaban/product/
  • This is one of the preferred choice DOACs. Milk levels are low. Although rivaroxaban has a high oral bioavailability, very low levels are expected in milk due to its other pharmacokinetic properties, so infant exposure should still be minimal. https://www.sps.nhs.uk/articles/using-oral-anticoagulants-during-breastfeeding/

Dabigatran (Pradaxa ®) compatible with breastfeeding

  • There are no studies on the transfer of dabigatran to breast milk. The molecular weight is large (628 Daltons) and the oral bioavailability is low (6.5%); therefore, clinically relevant levels are not expected to occur in a breastfed infant. (Hale).
  • In adults, less than 7% of dabigatran is absorbed orally in its prodrug form of dabigatran etexilate mesylate; dabigatran itself is not absorbed orally. Preliminary data from 2 individuals indicate that dabigatran is poorly excreted into breastmilk and unlikely to affect the breastfed infant. If the mother requires dabigatran, it is not a reason to discontinue breastfeeding. Because data are limited, monitor preterm or newborn infants for signs of bleeding. (Lactmed https://www.ncbi.nlm.nih.gov/books/NBK500744/
  • Its low oral bioavailability (EMA 2018, Blech 2008) hinders transfer to infant plasma via breastmilk, except in premature infants and the immediate neonatal period when there may be increased intestinal permeability.It is the oral anticoagulant with the lowest excretion in breast milk (Daei 2021). https://www.e-lactancia.org/breastfeeding/dabigatran-etexilate/product/
  • This is one of the preferred choice DOACs. Milk levels are likely to be low. Dabigatran etexilate is one of the largest of the DOAC molecules and has a large volume of distribution, therefore it would be expected to pass into breast milk in low amounts. Milk levels were tested from two breastfeeding women who took dabigatran etexilate 220mg as a single dose. The relative infant dose was calculated to be between 0.01 and 0.07%. The infants did not receive any breast milk during this time. Infant absorption is likely to be low. Dabigatran etexilate also has very low oral bioavailability, so the infant is unlikely to absorb clinically significant amounts from the breast milk. It is therefore very unlikely that the infant would get any side-effects.https://www.sps.nhs.uk/articles/using-oral-anticoagulants-during-breastfeeding/

Apixaban(Eliquis®) and Edoxaban (Lixiana®) due to limited research should not be prescribed during breastfeeding.

Topical preparations and breastfeeding

There are so many reasons that we need to apply creams, lotions, ointments and pastes to our bodies when breastfeeding. There is poor absorption of most products applied topically and most can be used without interrupting breastfeeding. These include:

  • Moisturizers/emollients used to soothe skin e.g Diprobase ® , Dermol ® , E45 ® , Aveeno ® , Cetraben
  • Topical steroids to soothe eczema should be applied sparingly regardless of breastfeeding and accompanied by emollients to keep skin supple eg Betnovate ®, Eumovate ® , Elocon ® , Hydrocortisone. They can be applied to the nipple very sparingly for short periods of time after feeds without needing to wash off as this may further damage skin. Moisturisers should be used to keep the skin supple but not soggy.
  • Bath emollients and shower gels to soothe irritated skin e.g Oilatum ®, E45 ® , Aveeno ®
  • Creams to treat cold sores e.g anti viral acyclovir (Zovirax ®), Compeed patches ®
  • Antiseptic creams e.g Savlon ®, Germolene ®, Dettol ® for minor wounds.
  • Antibacterial creams e.g fucidic acid (Fucidin ®), muciprocin (Bactroban) can be applied sparingly after feeds without need to wash off
  • Preparations to treat corns, warts and veruccas e.g Bazuka ® , Scholl products, Wartner ®
  • Creams to treat athletes food e.g terbinafine (Lamisil ® ), clotrimazole (Canesten ® ), Mycota ® , Mycil ®, Daktarin ®, Scholl products
  • Anti inflammatory gels and creams eg ibuprofen (Ibugel ® ), Diclofenac (Voltarol ® ), Deep Heat ® , Tiger Balm® , taking care not to use these where baby can rub into eyes
  • Medicated shampoos and lotions eg BetaCap ® , Selsun ®, Polytar ®
  • Head lice treatment https://breastfeeding-and-medication.co.uk/fact-sheet/head-lice-and-breastfeeding

Hayfever and breastfeeeding live video and powerpoint training

This is the beginning of the hayfever season with the sun coming out so today I recorded the video about the compatibility of drugs to treat symptoms and breastfeeding

I’ve also uploaded the powerpoint which I used to present this that you can share


Hayfever and breastfeeding powerpoint

Preferred treatment

  • Non sedating antihistamine e.g cetirizine, loratadine, fexofenadine
  • Nasal sprays which act locally e.g. Beconase®, Flixonase®, Mometasone, Nasocort®, Dymista®
  • Eye Drops which act locally e.g sodium cromoglycate

Drugs which may cause drowsiness in mother and nursling may reduce supply e.g acrivastine (Benadryl ® , chlorpheniramine (Piriton ®), promethazine (Phenergan ®)


Technetium 99 studies and Breastfeeding

Earlier this year I had the pleasure of working with Rachel Bidder and others at Swansea Bay University Health Board on compiling information on Having a Tc‑99m Diagnostic Study whilst breastfeeding. Subsequently the information was shared in a presentation to the BNMS conference. In addition, the local team amended their information on MRI and CT to be more breastfeeding friendly.

The information from the Swansea team is reproduced here with their permission. If you have questions regarding expressing and storing, please contact your local breastfeeding team. My thanks to Rachel for allowing me to share this


The vast majority of the radioactivity will be excreted via urine; however, a small amount will be excreted in breast milk. There are some precautions to follow to minimise the radiation dose babies receive. Radioactivity decays over time, meaning that not only will your body excrete it but the radioactivity itself will reduce. For Tc-99m, the radioactivity reduces by half every 6 hours, called the half-life. By following the advice in this leaflet (based on the ARSAC Notes for Guidance, 2022 and Drugs and Lactation Database, 2006), the radiation dose to your child from breastfeeding should be less than half of the annual natural background dose.
The disruption to your breastfeeding depends on the type of diagnostic study you are having. The interruption times given in this leaflet do not apply during the period of early lactation when colostrum is being secreted.

Before Your Appointment
All patients should ‘bank’ at least one feed before their appointment. Do this by expressing milk and storing it appropriately. Check the required breastfeeding interruption time for your scan using the table . It is recommended that you bank enough milk to feed your child over the length of this interruption period. If this is not possible for you then consider an alternative method for feeding your baby over this interruption period, such as using formula. Just before your appointment, you should feed your baby naturally.
After Your Appointment
You should not resume breastfeeding until after the total required period of interruption, as given for your study type in the table on the back of this leaflet. During this period of interruption, you should regularly express milk as fully as possible. This milk should not be used at this point. You can feed your baby during this time using a previously ‘banked’ feed. All milk expressed during the interruption time should either be discarded or stored in the freezer for at least 60 hours after your appointment. After 60 hours (10 half-lives), the radiation will have decayed to a safe level, and the stored milk can be used to feed (there is a small risk with this) or to bathe your baby as you please.
Once the interruption period has passed, you can continue to breastfeed your baby as normal.
Breastfeeding can be undertaken following subsequent pregnancies. Even if you have difficulty
expressing milk, the radioactivity will decay over time and will not be ‘stuck’ in your milk.


Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed
radioactive sources. Administration of Radioactive Substances Advisory Committee. Feb 2023


“The patient should interrupt breastfeeding for a period of time to ensure that the effective dose received by the infant is less than 1mSv”
To tell a mother with a neonate not to breastfeed for a period of time risks her developing mastitis and will undoubtedly have an impact on her ability in the future to breastfeed
Healthcare professionals have a duty to protect the breastfeeding relationship to support the health of the patient and the breastfeeding infant

See also:

Drugs and Lactation Database (LactMed) https://www.ncbi.nlm.nih.gov/books/NBK501922/

Hale TW Medications and Mothers Milk Online access

Bowel cleansing before colonoscopy and breastfeeding

Just recently I have been contacted by several mothers who were told that they cant breastfeeding during the 24 hour period of bowel prep prior to a colonoscopy or for 24 hours following the procedure under sedation. This is not supported by research and understanding of the pharmacokinetics of the drugs used. It is also a potential risk in that the mother may develop blocked ducts or mastitis necessitating antibiotics if she is unable to express her milk, or in many cases hasn’t been advised to! Not all babies will drink from a bottle so may become dehydrated. Some babies are allergic to cow’s milk protein and may be compromised by 3 days of artificial formula. Hence this fact sheet on the bowel preparations generally used.

It is acceptable to breastfeed as normal during bowel prep. The mother should drink freely of the allowed clear fluids. Someone may be needed to look after the baby during rapid need to evacuate bowels – unless you have taken these products you cant begin to understand the urgency!

PDF of information available


An increasing number of breastfeeding mothers are having colonoscopies to investigate gut problems. The first stage of a colonoscopy is the use of a strong laxative and 24 hours of a fluid only diet to clear out the gut so that the professionals can see the gut in its entirety completely.

Many mothers worry that not eating for 24 hours will reduce their milk supply. Fasting does drop the supply a small amount for some women but frequent feeds seem to overcome problems. It is important to keep drinking the clear fluids which are allowed in order not to dehydrate.

From experience you may find that you need someone else in the house to take the baby urgently when you have to rush to the toilet – there is no waiting! You may find otherwise that you end up feeding whilst on the loo for practical reasons. The bowel washouts produce considerable urgency


One of the most commonly used laxative agents to clear the gut is Movicol ® otherwise known as polyethylene glycol- electrolyte solution. It is a saline laxative which is not absorbed from the gut but pulls water into the bowel to wash the contents out. Because it is not absorbed from the gut it cannot get into breastmilk and would not affect the baby.


This dual sachet product contains macrogol and electrolytes in 2 different sachets, Because it is not absorbed from the gut it cannot get into breastmilk and would not affect the baby.


Sodium picosulfate is not absorbed from the gastrointestinal tract, and its active metabolite, which is absorbed, is not detectable in breastmilk. Breastfeeding can continue as normal.

KleanPrep ®

KleanPrep contains  macrogol 3350 , an osmotic laxative with a high molecular weigh and zero oral bioavailabilty. Like Moviprep it  accumulates water into the GI tract, where it acts as a laxative. It would be very unlikely to enter the plasma of the mother, or milk.


The ingredients magnesium carbonate and citric acid will form an osmotic laxative by pulling water into the bowel and stimulating the bowel to evacuate. Poor oral absorption of magnesium make it unlikely that any will be absorbed from milk to affect the breastfed baby.


Senna is a stimulant laxative. Its key ingredient (anthraquinone), is believed to increase bowel activity due to secretion into the colon. It may produce abdominal cramps. In one study of 23 women who received Senokot none was detectable in their milk.[1] Of 15 mothers reporting loose stools, two infants had loose stools (Werthmann 1973). However, in a randomized, double-blind trial comparing Senokot tablets to placebo, of the women in the study, 126 breastfed their infants and took senna while 155 control mothers breastfed their infants. There was no difference in the percentages of infants in the active and control groups with loose stools or diarrhoea (Shelton 1980). In this study 8 doses were taken. In bowel preparation a single dose only is used.

Werthmann MW Jr, Krees SV. Quantitative excretion of Senokot in human breast milk. Med Ann Dist Columbia. 1973;42:4-5.

Shelton MG. Standardized senna in the management of constipation in the puerperium. A clinical trial. S Afr Med J. 1980;57:78-80.

Phosphate enema (Fleet®)

Sodium phosphate is a saline laxative which sucks water into the lumen of the bowel. Whilst some phosphate may get into the plasma, it is very unlikely to change the levels in milk. The oral bioavailabilty is zero to 20%. Use of phosphate enemas should not require interruption of breastfeeding (LactMed)

Bisacodyl (Dulcolax ®)

Bisacodyl is poorly absorbed from the gut (oral bioavailabilty <5%)  and so reaches low levels in breastmilk. It is a stimulant laxative. Breastfeeding can continue as normal

For information on sedatives  (midazolam, fentanyl, pethidine) used in colonoscopies see separate fact sheet . These also do not preclude normal breastfeeding as soon as the mother is awake and alert.

Ectopic Pregnancy and Breastfeeding

Sadly our family has experienced the tragedy of an ectopic pregnancy and the loss of a very brief dream. This has made me much more aware of the incidence and risk of this condition over. So some more facts – as my friend commented today I hate to waste any opportunity to educate!

I have also heard from several mothers who have been diagnosed with an ectopic pregnancy. They have variously been told that they cant breastfeed again for 2 months and 3 months. One distraught mother planned to pump and dump her milk for 3 months with the hope that she could return to breastfeeding later.

Ectopic pregnancy is a common, occasionally life-threatening condition, that affects 1 in 80 pregnancies. An ectopic pregnancy is when a fertilised egg implants itself outside of the womb, usually in one of the fallopian tubes. Symptoms usually develop between the 4th and 12th weeks of pregnancy. Women with an ectopic pregnancy may still be breastfeeding and wish to continue which can be supported.


  • Ongoing bleeding that is sometimes red or brown/black and watery (like “prune juice”) should be investigated. The bleeding may be heavier or lighter than usual, but pregnancy test is still positive
  • One-sided pain in your tummy which may be persistent or intermittent or a generalised discomfort with bloating and a feeling of fullness (not associated with eating) when lying down.
  • Shoulder tip pain which is often described as pain unlike any you have ever experienced before. (Ectopic Pregnancy Trust)


Your GP will refer you urgently to the early pregnancy unit at your local hospital. You may have your Human Chorionic Gonadotropin (HCG levels) measured over a period of several days. If you are having a normal pregnancy these should double approximately every 48 hours. A smaller increase can indicate a risk of  of this being an ectopic pregnancy but this will be confirmed with ultrasound scans, initially across your tummy. It is likely that a transvaginal (internal) ultrasound scan will be required where a specialised probe is placed into the vagina to get a more detailed look at the reproductive organs.

Unfortunately, if it is confirmed over a period that you have an ectopic pregnancy it is not possible to save the pregnancy and it must be removed either by surgery or the use of methotrexate. The cells have not been able to be nourished and can never develop into the baby you thought you were expecting which can be hard to deal with.

Rupture of ectopic pregnancy

In a few cases, an ectopic pregnancy can grow large enough to split open the fallopian tube. This is known as a rupture which can be very serious, and surgery needs to be carried out as soon as possible.

Signs of a rupture include a combination of:

  • a sharp, sudden and intense pain in your tummy
  • feeling very dizzy or fainting
  • feeling sick
  • looking very pale (NHS Choices)

Methotrexate and breastfeeding

Mothers who are currently breastfeeding an older child can continue 24 hours after the methotrexate is administered.

“It is apparent that the concentration of methotrexate in human milk is minimal, although due to the toxicity of this agent and the unknown effects on rapidly developing neonatal gastrointestinal cells, it is probably wise to pump and discard the mother’s milk for a minimum of 24 hours post dose if given as a single dose (e.g. 50 mg/m2 IM for ectopic pregnancy).

The period in which the mother discards her milk may require extending (consider 4 days of interruption) if the dose used is quite high (>75mg). (Hale 2023). This is due to lack of data from research on accumulation in infant tissues rather than levels in breastmilk.

In a case report of a woman receiving 92 mg IM daily for 3 days (Baker T, Datta P, Rewers-Felkins K, Hale TW. High-dose methotrexate treatment in a breastfeeding mother with placenta accreta: a case report. Breastfeed Med. 2018 Jul/Aug;13(6):450-452 ), milk levels were collected and assayed for methotrexate although she was advised not to breastfeed.dose. Both methotrexate and its metabolite 7-hydroxymethotrexate levels in milk were exceedingly low. On day 2 of therapy, the average milk concentration of methotrexate was 8.6 ng/mL. The maximum concentration of methotrexate occurred at 2 hours and was found to be 16.9 ng/mL. The levels gradually receded and were 4.9 ng/mL at 24 hours. The relative infant dose of methotrexate (RID) was calculated at 0.11%. The half life of methotrexate is quoted as 8-15 hours (Hale 2023).

Infant Monitoring: Should patient resume breastfeeding more than 24 hours after the last dose of maternal therapy, monitor the infant for vomiting, diarrhoea, blood in the vomit, stool or urine. Lab work could be drawn if clinical signs of liver or renal dysfunction, anaemia, thrombocytopenia or an inability to fight infection.

Lactmed reports a study of one mother who was given a single intramuscular dose of 65 mg (50 mg/square meter) of methotrexate for ectopic pregnancy. Six milk samples were obtained from 1 to 24 hours after the dose. Methotrexate was undetectable (<22.7 mcg/L) in all milk samples (Tanaka 2009). In some 20% of cases more than one cycle of methotrexate is required to expel the products of conception. For each cycle breastfeeding should be avoided for 24 hours.

Hale quotes a milk plasma ratio of > 0.08 and relative infant dose of 0.13% – 0.95%. Peak serum concentrations appear 30-60 minutes after intra muscular dose (Jones 2018). Pharmacokinetic data is very variable as there in considerable inter individual variation (Martindale 2017).

Methotrexate and breastfeeding

There is not much information about methotrexate and breastfeeding, but it shows that methotrexate passes into breast milk in tiny amounts. Your doctor or specialist will advise what’s best for you and your baby.

If your weekly dose of methotrexate is 25mg or less, it may be possible to breastfeed. However, you must not breastfeed for 24 hours after taking your medicine. Your midwife or health visitor can give you advice about how to feed your baby while you wait 24 hours. https://www.nhs.uk/medicines/methotrexate/pregnancy-breastfeeding-and-fertility-while-taking-methotrexate/

For more information on methotrexate administration, side effects and monitoring see www.ectopic.org.uk/patients/treatment/

Ectopic pregnancy and breastfeeding fact sheet

Breastfeeding after surgery

After surgery breastfeeding can continue as normal as soon as you are awake and alert. If your nursling is unable to stay in hospital with you, you may need to express to avoid engorgement/blocked duct and to maintain your supply. Your expressed milk can be given to your baby at home. There is no need to pump and dump.

Vaccinations and Breastfeeding

Taken from Breastfeeding and Chronic Medical Conditions available from Amazon.

Most vaccinations can be undertaken during breastfeeding as they do not pass into breastmilk. For detailed information please check the Green Book which has sections for breastfeeding. https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book

  • Chicken pox (varicella): compatible with normal breastfeeding
  • Hepatitis A: compatible with normal breastfeeding
  • Hepatitis B: Vaccinations are routinely offered to healthcare professionals who may come into contact with body fluids.  Compatible with normal breastfeeding
  • Influenza: compatible with normal breastfeeding
  • Meningococcal C: Immunization of pregnant or lactating women with meningococcal vaccine increased the specific secretory IgA content of milk. compatible with normal breastfeeding
  • MMR Injections: A breastfeeding mother can have an MMR injection if she is not rubella immune.  Although live vaccines multiply within the mother’s body, the majority have not been demonstrated to be excreted in human milk (Bohlke K, Galil K, Jackson LA, et al. Postpartum varicella vaccination: is the vaccine virus excreted in breast milk? Obstet Gynecol 2003; 102:970–7).  Although rubella vaccine virus might be excreted in human milk, the virus usually does not infect the infant.  If infection does occur, it is well-tolerated because the virus is attenuated.  Inactivated, recombinant, subunit, polysaccharide, conjugate vaccines, and toxoids pose no risk for mothers who are breast feeding or for their infants.
  • Pneumonia: compatible with normal breastfeeding
  • Polio: The injectable polio vaccine is inactivated and poses no risk when given to mothers who are breastfeeding.  The oral vaccine may reduce the production of antibodies by the infant and immunisation of the mother before the infant reaches 6 weeks of age is not recommended.
  • Tetanus Vaccination: One study of previously vaccinated infants found that at 21 to 40 months of age breastfed infants had higher IgG levels against diphtheria, higher secretory IgA levels in saliva against diphtheria and tetanus and higher faecal IgM against tetanus than formula-fed infants.  There is no contra indication to a breastfeeding mother having this vaccination.
  • Tuberculin and BCG: There is no reason to avoid tuberculin testing during breastfeeding nor to avoid use of the BCG vaccine unless the mother is immunocompromised.
  • Typhoid Vaccination: One study of previously vaccinated infants found that at 21 to 40 months of age breastfed infants had higher IgG levels against diphtheria, higher secretory IgA levels in saliva against diphtheria and tetanus and higher faecal IgM against tetanus than formula-fed infants.  There is no contra indication to having the vaccination and continuing to breastfeed.
  • Whooping Cough: there is no evidence of risk of vaccinating breastfeeding mothers with the whooping cough (pertussis) vaccine as part of the campaign to protect new-born babies.

See also SPS Giving vaccines and breastfeeding


Breastfeeding and Medication, Wendy Jones

Follow Us

Recent Posts